The 6 analysts offering 12-month price forecasts for Arbutus Biopharma Corp have a median target of 7.50, with a high estimate of 10.00 and a low estimate of 4.00. The median estimate represents a +85.64% increase from the last price of 4.04.
The current consensus among 6 polled investment analysts is to Buy stock in Arbutus Biopharma Corp. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.23
Reporting Date Mar 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.